Generic Drug Markets: U.S. vs. Europe. Prices, Volumes, IP Strategy, and the $445 Billion Savings Gap
Why This Comparison Matters Now The generic pharmaceutical industry generated $445 billion in U.S. system savings in 2023 alone, according […]
Insights
US Biosimilars: The Complete Barrier Map for IP Teams, Payers, and Portfolio Managers
Key Takeaways (Executive Summary) Part I: The BPCIA Framework — Why ‘Abbreviated’ Is a Misnomer What the Biologics Price Competition
US Biosimilars: The Complete Barrier Map for IP Teams, Payers, and Portfolio Managers Read Post »
The Biosimilar Paradox: 2026 Market Report on Systemic Challenges, Policy Collisions, and the Future of Biologic Competition
Executive Summary As of January 2026, the United States biosimilars market stands at a critical juncture, characterized by a fundamental
Biotech’s $400B Problem: The Patent, IP, and Competitive Intelligence Playbook Every Pharma Executive Needs
The path from discovery to commercial dominance has never been more expensive, more legally treacherous, or more dependent on intelligence
Understanding Pharmaceutical Competitor Analysis
Strategic Pharmaceutical Competitor Analysis: Intellectual Property Moats and Market Entry Dynamics Pharmaceutical firms operate in an environment where patent expiration
Understanding Pharmaceutical Competitor Analysis Read Post »
FDA Unapproved Drugs: The $7.5 Billion 505(b)(2) Opportunity Most Pharma Execs Are Ignoring
The Anomaly That Keeps Paying Here is a fact that surprises most people who work outside drug regulatory affairs: hundreds
Global Pharmaceutical Export Expansion: The Definitive Playbook for IP-Led Market Leadership
Section 1: The Global Pharmaceutical Trade Architecture: Flow Mapping, Hub Dynamics, and Value Chain Positioning The global pharmaceutical export market
Drug Patent Fortress Strategy: The Playbook for Pharma IP Teams
I. Executive Summary The pharmaceutical patent fortress is no longer just a legal concept. It is the primary financial architecture
Drug Patent Fortress Strategy: The Playbook for Pharma IP Teams Read Post »
Generic Drug Development: The Complete IP, Regulatory, and Portfolio Strategy Guide
1. The Market in Numbers: What the Patent Cliff Actually Means for Generic Opportunity Scale, Growth, and the Savings Paradox
Generic Drug Development: The Complete IP, Regulatory, and Portfolio Strategy Guide Read Post »
